Curetis to Hold Annual General Shareholders' Meeting on June 23, 2017
(Thomson Reuters ONE) -
Curetis /
Curetis to Hold Annual General Shareholders' Meeting on June 23, 2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Curetis to Hold Annual General Shareholders' Meeting on June 23, 2017
- Company nominates Dr Nils Clausnitzer for election into its Supervisory Board
Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 8, 2017 - Curetis
N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of
next-level molecular diagnostic solutions, today published the invitation to its
annual general shareholders' meeting ("AGM").
Curetis will hold its AGM on June 23, 2017, at Steigenberger Hotel,
Stationsplein Zuid - West 951, 1117 CE Schiphol - Oost/Amsterdam, the
Netherlands. The meeting is scheduled to commence at 13:30 hours CEST; local
registration starts at 13:00 hours CEST.
In addition, Curetis will be offering electronic pre-voting starting on
Saturday, May 27, 2017, at 08:00 hours CEST at www.abnamro.com/evoting.
A copy of the convening notice for the AGM, including a description of the
formalities to participate in the AGM, is available at
http://www.curetis.com/en/investors/share-information/annual-general-
meeting.html.
Primary resolutions on the agenda of the AGM relate to changes in the
Supervisory Board, specifically the proposed election of Dr Nils Clausnitzer
(Senior Vice President and President, EMEA-APAC Lab and Distribution Services of
VWR International llc/ VWR GmbH) as a new Supervisory Board member for a three-
year term until the ordinary general shareholder meeting 2020, and the re-
election of Dr Holger Reithinger and Dr Rudy Dekeyser for another one-year term,
respectively.
###
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million.
Furthermore, Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies,
and has entered into several international distribution agreements covering many
countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of
Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximizing the
R&D and related scientific and business opportunities of the GEAR assets
acquired in 2016 for the entire Curetis Group.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Curetis_Logo:
http://hugin.info/171382/R/2102521/797351.jpg
20170508_Curetis_PR_EN_AGM invite:
http://hugin.info/171382/R/2102521/797348.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 08.05.2017 - 08:27 Uhr
Sprache: Deutsch
News-ID 540765
Anzahl Zeichen: 7006
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 142 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis to Hold Annual General Shareholders' Meeting on June 23, 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
